Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2018 08:30 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial Officer

COPENHAGEN, Denmark, April 02, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address...
March 28, 2018 16:01 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Reports Full Year 2017 Financial Results

- Rare Disease Endocrinology Pipeline Advances, with Significant Milestones Anticipated Over the Next Twelve Months - - Conference Call Today at 4:30...
March 19, 2018 07:01 ET | Source: Ascendis Pharma A/S

Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018

- Baseline demographics of TransCon Growth Hormone phase 3 heiGHt Trial presented - - Multiple ascending dose cohorts from TransCon PTH phase 1 clinical trial reinforced infusion-like profile...
March 16, 2018 07:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28

COPENHAGEN, Denmark, March 16, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
February 21, 2018 23:45 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

COPENHAGEN, Denmark, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering...
February 20, 2018 16:01 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

COPENHAGEN, Denmark, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public...
February 08, 2018 16:15 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Participation in Leerink Partners 7th Annual Global Healthcare Conference

COPENHAGEN, Denmark, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant...
January 08, 2018 08:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH

COPENHAGEN, Denmark, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
January 03, 2018 16:15 ET | Source: Ascendis Pharma A/S

Ascendis Pharma Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone for Pediatric Growth Hormone Deficiency

COPENHAGEN, Denmark, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
December 21, 2017 16:05 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Participation in 36th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...